Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally.
Outstanding track record with high growth potential.
Share Price & News
How has Pharming Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHARM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PHARM underperformed the Dutch Biotechs industry which returned 51.1% over the past year.
Return vs Market: PHARM exceeded the Dutch Market which returned -22.3% over the past year.
Price Volatility Vs. Market
How volatile is Pharming Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHere's Why We Think Pharming Group (AMS:PHARM) Is Well Worth Watching
3 weeks ago | Simply Wall StA Sliding Share Price Has Us Looking At Pharming Group N.V.'s (AMS:PHARM) P/E Ratio
1 month ago | Simply Wall StThe Pharming Group (AMS:PHARM) Share Price Is Up 292% And Shareholders Are Boasting About It
Is Pharming Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHARM (€0.93) is trading below our estimate of fair value (€1.81)
Significantly Below Fair Value: PHARM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHARM is good value based on its PE Ratio (16x) compared to the Biotechs industry average (39.6x).
PE vs Market: PHARM is poor value based on its PE Ratio (16x) compared to the Dutch market (14.7x).
Price to Earnings Growth Ratio
PEG Ratio: PHARM is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: PHARM is overvalued based on its PB Ratio (5.6x) compared to the XE Biotechs industry average (3.1x).
How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHARM's forecast earnings growth (36% per year) is above the savings rate (-0.2%).
Earnings vs Market: PHARM's earnings (36% per year) are forecast to grow faster than the Dutch market (13.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHARM's revenue (19.5% per year) is forecast to grow faster than the Dutch market (5.1% per year).
High Growth Revenue: PHARM's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHARM's Return on Equity is forecast to be high in 3 years time (26.7%)
How has Pharming Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHARM has high quality earnings.
Growing Profit Margin: PHARM's current net profit margins (21.4%) are higher than last year (18.5%).
Past Earnings Growth Analysis
Earnings Trend: PHARM has become profitable over the past 5 years, growing earnings by 14% per year.
Accelerating Growth: PHARM's earnings growth over the past year (44.8%) exceeds its 5-year average (14% per year).
Earnings vs Industry: PHARM earnings growth over the past year (44.8%) exceeded the Biotechs industry 16.1%.
Return on Equity
High ROE: PHARM's Return on Equity (34.6%) is considered high.
How is Pharming Group's financial position?
Financial Position Analysis
Short Term Liabilities: PHARM's short term assets (€106.5M) exceed its short term liabilities (€101.9M).
Long Term Liabilities: PHARM's short term assets (€106.5M) exceed its long term liabilities (€21.6M).
Debt to Equity History and Analysis
Debt Level: PHARM's debt to equity ratio (43.6%) is considered high.
Reducing Debt: PHARM's debt to equity ratio has increased from 0% to 43.6% over the past 5 years.
Inventory Level: PHARM has a low level of unsold assets or inventory.
Debt Coverage by Assets: PHARM's debt is covered by short term assets (assets are 2.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHARM is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: PHARM is profitable, therefore cash runway is not a concern.
What is Pharming Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHARM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PHARM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHARM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHARM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHARM's dividend in 3 years as they are not forecast to pay a notable one for the Dutch market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon de Vries (60yo)
Dr. Sijmen De Vries, also known as Simon, M.D., MBA has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and has also been its Chairman and Member of the Management Board since ...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD1.48M) is about average for companies of similar size in the Dutch market ($USD1.38M).
Compensation vs Earnings: Simon's compensation has been consistent with company performance over the past year.
|Chairman of Management Board & CEO||11.42yrs||€1.36m||1.1% €6.4m|
|CFO & Member of Management Board||4.5yrs||€655.00k||0.14% €812.1k|
|Chief Medical Officer & Member of Management Board||13.33yrs||€839.00k||0.42% €2.5m|
|Senior Vice President of Operations||0.67yr||no data||no data|
|Chief Scientific Officer||5.17yrs||no data||no data|
|Senior Vice President of Organisational Development||6.25yrs||no data||no data|
|VP & Head of Non-US Commercial Operations||3.25yrs||no data||no data|
|Senior VP & GM of Pharming USA||3.25yrs||no data||no data|
Experienced Management: PHARM's management team is considered experienced (4.8 years average tenure).
|Member of the Board of Supervisory Directors||12.92yrs||€68.00k||0.038% €220.4k|
|Chairman of the Board of Supervisory Directors||3.92yrs||€80.00k||0.066% €388.5k|
|Vice Chairman of the Board of Supervisory Directors||no data||€68.00k||0.070% €410.0k|
|Member of the Board of Supervisory Directors||11yrs||€71.00k||0.024% €138.7k|
|Member of the Board of Supervisory Directors||0.92yr||no data||no data|
Experienced Board: PHARM's board of directors are considered experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PHARM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.
Pharming Group N.V.'s company bio, employee growth, exchange listings and data sources
- Name: Pharming Group N.V.
- Ticker: PHARM
- Exchange: ENXTAM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €587.370m
- Shares outstanding: 634.99m
- Website: https://www.pharming.com
Number of Employees
- Pharming Group N.V.
- Darwinweg 24
- 2333 CR
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHGU.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 1998|
|PHARM||ENXTAM (Euronext Amsterdam)||Yes||Ordinary Shares||NL||EUR||Oct 1998|
|PHGN||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 1998|
|0QCO||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Oct 1998|
|PHGN||BRSE (Berne Stock Exchange)||Yes||Ordinary Shares||CH||CHF||Oct 1998|
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A; and protein replacement treatments for enzyme-defi ciency disorders, such as pompe and fabry diseases, as well as products for contrast induced nephropathy. The company has a partnership with China Shanghai Institute of Pharmaceutical Industry for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 00:32|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.